Alps Group Inc

AI-generated fair value estimate for this company.

Method: EV/Sales multiple valuation: TTM revenue ~$3.74M; applied a 2.0x EV/Sales multiple (reflecting real but early/cash-burning healthcare-services growth with no analyst coverage) for EV of ~$7.48M; subtracted net debt of ~$0.14M (debt $0.78M minus cash $0.64M); equity value ~$7.34M divided by ~166.4M shares outstanding.

Reasoning: Alps Group (post-SPAC Malaysia-based precision-oncology/organoid R&D and wellness services company) has negative net income (-$2.64M TTM) and negative free cash flow (-$1.68M TTM) with cash of only $0.64M against $0.78M debt and no analyst coverage, so a cash-flow DCF would be built on fabricated forecasts; a modest revenue multiple net of debt better reflects the going-concern/dilution risk despite the company's own reported ~44% revenue growth claim.